1
|
Demortier J, Vautier M, Chosidow O, Gallay L, Bessis D, Berezne A, Cordel N, Schmidt J, Smail A, Duffau P, Jachiet M, Begon E, Gottlieb J, Chasset F, Graveleau J, Marque M, Cesbron E, Forestier A, Josse S, Kluger N, Beauchêne C, Le Corre Y, Pagis V, Rigolet A, Guillaume-Jugnot P, Authier FJ, Guilain N, Streichenberger N, Leonard-Louis S, Boussouar S, Landon-Cardinal O, Benveniste O, Allenbach Y. Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology (Oxford) 2023; 62:3932-3939. [PMID: 37010495 DOI: 10.1093/rheumatology/kead154] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Revised: 02/26/2023] [Accepted: 03/10/2023] [Indexed: 04/04/2023] Open
Abstract
OBJECTIVE Among specific autoantibodies in DM, the anti-small ubiquitin-like modifier activating enzyme (SAE) antibody is rare. We aim to describe the clinical characteristics, cancer prevalence, and muscle pathology of anti-SAE-positive DM. METHODS Patients with a diagnosis of DM and sera positive for the anti-SAE antibody were recruited from 19 centres in this retrospective observational study. The available muscular biopsies were reviewed. We conducted a comparison with anti-SAE-negative DM and a review of the literature. RESULTS Of the patients in the study (n = 49), 84% were women. Skin involvement was typical in 96% of patients, with 10% having calcinosis, 18% ulceration and 12% necrosis; 35% presented with a widespread skin rash. Muscular disease affected 84% of patients, with mild weakness [Medical Research Council (MRC) scale 4 (3, 5)], although 39% of patients had dysphagia. Muscular biopsies showed typical DM lesions. Interstitial lung disease was found in 21% of patients, mainly with organizing pneumonia pattern, and 26% of patients showed dyspnoea. Cancer-associated myositis was diagnosed in 16% of patients and was responsible for the majority of deaths, its prevalence being five times that of the general population. IVIG therapy was administered to 51% of the patients during the course of the disease. Comparison with anti-SAE-negative DM (n = 85) showed less and milder muscle weakness (P = 0.02 and P = 0.006, respectively), lower creatinine kinase levels (P < 0.0001) and less dyspnoea (P = 0.003). CONCLUSION Anti-SAE positive DM is a rare subgroup associated with typical skin features but a potentially diffuse rash, a mild myopathy. Interstitial lung disease defines an organizing pneumonia pattern. Cancer associated DM prevalence is five times that of the general population. TRIAL REGISTRATION ClinicalTrials.gov, http://clinicaltrials.gov, NCT04637672.
Collapse
Affiliation(s)
- Juliette Demortier
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - Mathieu Vautier
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Sorbonne Université, AP-HP, Paris, France
| | - Olivier Chosidow
- Department of Dermatology, Henri Mondor University Hospital, Université Paris-Est Créteil, AP-HP, Créteil, France
| | - Laure Gallay
- Department of Internal Medicine and Clinical Immunology, Edouard Herriot University Hospital, Claude Bernard University Lyon1, Lyon, France
| | - Didier Bessis
- Department of Dermatology, University Hospital Center of Montpellier, Montpellier, France
| | - Alice Berezne
- Department of Internal Medicine, CHR Annecy-Genevois, Annecy, France
| | - Nadège Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, Guadeloupe and Normandie University, UNIROUEN, IRIB, Inserm, U1234, Rouen, France
| | - Jean Schmidt
- Department of Internal Medicine and Clinical Immunology, Amiens-Picardie Nord University Hospital, Amiens, France
| | - Amar Smail
- Department of Internal Medicine and Clinical Immunology, Amiens-Picardie Nord University Hospital, Amiens, France
| | - Pierre Duffau
- Department of Internal Medicine, Saint André, Bordeaux University Hospital, Bordeaux, France
| | - Marie Jachiet
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Edouard Begon
- Department of Dermatology, René Dubos Hospital, Pontoise, France
| | - Jeremy Gottlieb
- Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, Université Paris-Sud, AP-HP, Le Kremlin-Bicêtre Cedex, France
| | - François Chasset
- Department of Dermatology, Tenon Hospital, Sorbonne Université, AP-HP, Paris, France
| | - Julie Graveleau
- Department of Internal Medicine, CH de St Nazaire, St Nazaire, France
| | - Myriam Marque
- Department of Dermatology, Caremeau Hospital, Nîmes University Hospital, Nîmes, France
| | - Elise Cesbron
- Department of Dermatology, Le Mans Hospital Center, Le Mans, France
| | - Amandine Forestier
- Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Mutualiste, Grenoble, France
| | - Séverine Josse
- Department of Internal Medicine and Clinical Immunology, Dieppe Hospital, Dieppe, France
| | - Nicolas Kluger
- Department of Dermatology, Helsinki University Hospital, Helsinki, Finland
| | | | - Yannick Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
| | - Valentine Pagis
- Department of Internal Medicine and Clinical Immunology, Beaujon Hospital, AP-HP, Paris, France
| | - Aude Rigolet
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Sorbonne Université, AP-HP, Paris, France
| | - Perrine Guillaume-Jugnot
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Sorbonne Université, AP-HP, Paris, France
| | - François-Jérôme Authier
- Department of Pathology, Henri-Mondor University Hospital, Institut Mondor de Recherche Biomédicale, INSERM, Centre de Reference pour les Maladies Neuromusculaires of Nord-Est-Île de France, Université Paris-Est Créteil, AP-HP, Créteil, France
| | - Nelly Guilain
- Department of Pathology, Amiens Picardie University Hospital, Amiens, France
| | | | - Sarah Leonard-Louis
- Neuropathology Department, Pitié-Salpêtrière University Hospital, Sorbonne Université, AP-HP, Paris, France
| | - Samia Boussouar
- ICT Cardiothoracic Imaging Unit, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Paris, France
| | - Océane Landon-Cardinal
- Division of Rheumatology, Centre Hospitalier de l'Université de Montréal (CHUM), CHUM Research Center, Department of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Olivier Benveniste
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Sorbonne Université, AP-HP, Paris, France
| | - Yves Allenbach
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Sorbonne Université, AP-HP, Paris, France
| |
Collapse
|
2
|
Guillaume-Jugnot P, Shor N, Bielle F, Zavanone C, Barete S, Maillart E. Atypical multiple sclerosis associated with indolent systemic mastocytosis treated by cladribine. Rev Neurol (Paris) 2023; 179:925-927. [PMID: 37500352 DOI: 10.1016/j.neurol.2023.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2022] [Revised: 12/14/2022] [Accepted: 03/11/2023] [Indexed: 07/29/2023]
Affiliation(s)
- P Guillaume-Jugnot
- Department of Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
| | - N Shor
- Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| | - F Bielle
- Department of Neuropathology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, Paris, France
| | - C Zavanone
- Department of Neurology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| | - S Barete
- Unit of Dermatology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; Reference center for mastocytosis (CEREMAST), Hôpital Pitié-Salpêtrière, Paris, France
| | - E Maillart
- Department of Neurology, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| |
Collapse
|
3
|
Landon-Cardinal O, Guillaume-Jugnot P, Toquet S, Sbeih N, Rigolet A, Champtiaux N, Dorgham K, Gorochov G, Meyer A, Anquetil C, Barete S, Benveniste O, Allenbach Y. JAK inhibitors for the treatment of adult dermatomyositis: A pilot study. J Am Acad Dermatol 2023; 88:924-926. [PMID: 36356704 DOI: 10.1016/j.jaad.2022.10.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 09/26/2022] [Accepted: 10/27/2022] [Indexed: 11/09/2022]
Affiliation(s)
- Océane Landon-Cardinal
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France; Department of Medicine, Université de Montréal, Division of Rheumatology and Research Center, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
| | - Perrine Guillaume-Jugnot
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Ségolène Toquet
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Nabiha Sbeih
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Aude Rigolet
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Nicolas Champtiaux
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Karim Dorgham
- Sorbonne Université, Inserm, Centre d'immunologie et des maladies infectieuses-Paris (CIMI-PARIS), Département d'Immunologie, AP-HP Hôpital Pitié-Salpêtrière, Paris, France
| | - Guy Gorochov
- Sorbonne Université, Inserm, Centre d'immunologie et des maladies infectieuses-Paris (CIMI-PARIS), Département d'Immunologie, AP-HP Hôpital Pitié-Salpêtrière, Paris, France
| | - Alain Meyer
- Service de physiologie et d'explorations fonctionnelles musculaires, Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Céline Anquetil
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Stéphane Barete
- Department of Dermatology, Pitié-Salpêtrière University Hospital, Sorbonne Université, Paris, France
| | - Olivier Benveniste
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France
| | - Yves Allenbach
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Inserm U974, Sorbonne Université, Paris 6, Paris, France.
| |
Collapse
|
4
|
Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, Boussouar S, Nguyen LS, Procureur A, Stein F, Fenioux C, Devos P, Gougis P, Dres M, Demoule A, Psimaras D, Lenglet T, Maisonobe T, Pineton DE Chambrun M, Hekimian G, Straus C, Gonzalez-Bermejo J, Klatzmann D, Rigolet A, Guillaume-Jugnot P, Champtiaux N, Benveniste O, Weiss N, Saheb S, Rouvier P, Plu I, Gandjbakhch E, Kerneis M, Hammoudi N, Zahr N, Llontop C, Morelot-Panzini C, Lehmann L, Qin J, Moslehi JJ, Rosenzwajg M, Similowski T, Allenbach Y. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov 2023; 13:1100-1115. [PMID: 36815259 DOI: 10.1158/2159-8290.cd-22-1180] [Citation(s) in RCA: 34] [Impact Index Per Article: 34.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 01/05/2023] [Accepted: 02/13/2023] [Indexed: 02/24/2023]
Abstract
Immune-checkpoint-inhibitor (ICI)-associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and is highly fatal. We report the results of a strategy that included identification of individuals with severe ICI-myocarditis by also screening for and managing concomitant respiratory muscle involvement with mechanical ventilation, as well as treatment with CTLA4-fusion protein abatacept and the Janus-kinase inhibitor ruxolitinib. Forty cases with definite ICI-myocarditis were included with pathological confirmation of concomitant myositis in the majority of patients. In the first 10 patients, using recommended guidelines, myotoxicity-related fatality occurred in 60%, consistent with historical controls. In the subsequent 30 cases, we instituted systematic screening for respiratory muscle involvement coupled with active ventilation and treatment using ruxolitinib and abatacept. Abatacept dose was adjusted using CD86-receptor occupancy on circulating monocytes. Myotoxicity-related fatality rate was 3.4%(1/30) in these 30 patients vs.60% in 1st quartile(p<0.0001). These clinical results are hypothesis-generating and need further evaluation.
Collapse
Affiliation(s)
| | - Marie Bretagne
- Cochin Hospital, AP-HP, Paris Descartes University, Paris, France
| | | | | | | | | | | | - Lee S Nguyen
- Groupe Hospitalier Privé Ambroise Paré - Hartmann, Neuilly-sur-Seine, France
| | | | | | | | | | | | | | | | - Dimitri Psimaras
- Hôpitaux universitaires Pitié-Salpêtrière Charles Foix. Assistance Publique Hôpitaux de Paris (APHP), Paris, France, Paris, France
| | | | | | | | | | - Christian Straus
- Sorbonne Université, INSERM, UMRS1158, AP-HP, Hôpital Pitié-Salpêtrière, PARIS, France
| | | | - David Klatzmann
- UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy, Paris, France
| | | | | | | | | | | | | | | | | | | | | | - Nadjib Hammoudi
- Sorbonne Université, ACTION Study Group, INSERM UMR_S 1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
| | | | | | | | | | - Juan Qin
- University of California, San Francisco, San Fransisco, CA, United States
| | | | | | | | | |
Collapse
|
5
|
Comarmond C, Leclercq M, Leroux G, Marques C, Le Joncour A, Domont F, Hatte C, Toquet-Bouedec S, Guillaume-Jugnot P, Desbois AC, Vautier M, Rigolet A, Allenbach Y, Benveniste O, Saadoun D, Cacoub P. Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey'. Ann Rheum Dis 2023; 82:e30. [PMID: 33184046 DOI: 10.1136/annrheumdis-2020-219407] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 10/29/2020] [Indexed: 01/26/2023]
Affiliation(s)
- Cloé Comarmond
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France .,Sorbonne Université, Paris, France
| | - Mathilde Leclercq
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Gaëlle Leroux
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Cindy Marques
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
| | - Alexandre Le Joncour
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
| | - Fanny Domont
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Céline Hatte
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Ségolène Toquet-Bouedec
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,Sorbonne Université, Paris, France
| | - Perrine Guillaume-Jugnot
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Anne-Claire Desbois
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,Sorbonne Université, Paris, France
| | - Mathieu Vautier
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Aude Rigolet
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Yves Allenbach
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,Sorbonne Université, Paris, France.,DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
| | - Olivier Benveniste
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,Sorbonne Université, Paris, France.,DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
| | - David Saadoun
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,Sorbonne Université, Paris, France.,DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
| | - Patrice Cacoub
- Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.,Sorbonne Université, Paris, France.,DHU Inflammation, Immunopathologie, Biothérapie, Paris, France
| |
Collapse
|
6
|
Mariette X, Hermine O, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Yazdanpanah Y, Baron G, Perrodeau E, Vanhoye D, Kedzia C, Demerville L, Gysembergh-Houal A, Bourgoin A, Dalibey S, Raked N, Mameri L, Alary S, Hamiria S, Bariz T, Semri H, Hai DM, Benafla M, Belloul M, Vauboin P, Flamand S, Pacheco C, Walter-Petrich A, Stan E, Benarab S, Nyanou C, Montlahuc C, Biard L, Charreteur R, Dupré C, Cardet K, Lehmann B, Baghli K, Madelaine C, D'Ortenzio E, Puéchal O, Semaille C, Savale L, Harrois A, Figueiredo S, Duranteau J, Anguel N, Pavot A, Monnet X, Richard C, Teboul JL, Durand P, Tissieres P, Jevnikar M, Montani D, Bulifon S, Jaïs X, Sitbon O, Pavy S, Noel N, Lambotte O, Escaut L, Jauréguiberry S, Baudry E, Verny C, Noaillon M, Lefèvre E, Zaidan M, Le Tiec CLT, Verstuyft C, Roques AM, Grimaldi L, Molinari D, Leprun G, Fourreau A, Cylly L, Virlouvet M, Meftali R, Fabre S, Licois M, Mamoune A, Boudali Y, Georgin-Lavialle S, Senet P, Pialoux G, Soria A, Parrot A, François H, Rozensztajn N, Blin E, Choinier P, Camuset J, Rech JS, Canellas A, Rolland-Debord C, Lemarié N, Belaube N, Nadal M, Siguier M, Petit-Hoang C, Chas J, Drouet E, Lemoine M, Phibel A, Aunay L, Bertrand E, Ravato S, Vayssettes M, Adda A, Wilpotte C, Thibaut P, Fillon J, Debrix I, Fellahi S, Bastard JP, Lefèvre G, Fallet V, Gottenberg JE, Hansmann Y, Andres E, Bayer S, Becker G, Blanc F, Brin S, Castelain V, Chatelus E, Chatron E, Collange O, Danion F, De Blay F, Demonsant E, Diemunsch P, Diemunsch S, Felten R, Goichot B, Greigert V, Guffroy A, Heger B, Hutt A, Kaeuffer C, Kassegne L, Korganow AS, Le Borgne P, Lefebvre N, Martin T, Mertes PM, Metzger C, Meyer N, Nisand G, Noll E, Oberlin M, Ohlmann-Caillard S, Poindron V, Pottecher J, Ruch Y, Sublon C, Tayebi H, Weill F, Mekinian A, Abisror N, Jachiet V, Chopin D, Fain O, Garnier M, Krause le Garrec J, Morgand M, Pacanowski J, Urbina T, McAvoy C, Pereira M, Aratus G, Berard L, Simon T, Daguenel-Nguyen A, Antignac M, Leplay C, Arlet JB, Diehl JL, Bellenfant F, Blanchard A, Buffet A, Cholley B, Fayol A, Flamarion E, Godier A, Gorget T, Hamada SR, Hauw-Berlemont C, Hulot JS, Lebeaux D, Livrozet M, Michon A, Neuschwander A, Penet MA, Planquette B, Ranque B, Sanchez O, Volle G, Briois S, Cornic M, Elisee V, Jesuthasan D, Djadi-Prat J, Jouany P, Junquera R, Henriques M, Kebir A, Lehir I, Meunier J, Patin F, Paquet V, Tréhan A, Vigna V, Sabatier B, Bergerot D, Jouve C, Knosp C, Lenoir O, Mahtal N, Resmini L, Lescure FX, Ghosn J, BACHELARD A, BIRONNE T, BORIE R, BOUNHIOL A, BOUSSARD C, CHAUFFiER J, CHALAL S, CHALAL L, CHANSOMBAT M, CRESPIN P, CRESTANI B, DACONCEICAO O, DECONINCK L, DIEUDE P, DOSSIER A, DUBERT M, DUCROCQ G, FUENTES A, GERVAIS A, GILBERT M, ISERNIA V, ISMAEL S, JOLY V, JULIA Z, LARIVEN S, LE GAC S, LE PLUART D, LOUNI F, NDIAYE A, PAPO T, PARISEY M, PHUNG B, POURBAIX A, RACHLINE A, RIOUX C, SAUTEREAU A, STEG G, TARHINI H, VALAYER S, VALLOIS D, VERMES P, VOLPE T, Nguyen Y, Honsel V, Weiss E, Codorniu A, Zarrouk V, De Lastours V, Uzzan M, Olivier O, Rossi G, Gamany N, Rahli R, Louis Z, Boutboul D, Galicier L, Amara Y, Archer G, Benattia A, Bergeron A, Bondeelle L, De Castro N, Clément M, Darmont M, Denis B, Dupin C, Feredj E, Feyeux D, Joseph A, Lengliné E, Le Guen P, Liégeon G, Lorillon G, Mabrouki A, Mariotte E, Martin de Frémont G, Mirouse A, Molina JM, Peffault de Latour R, Oksenhendler E, Saussereau J, Tazi A, Tudesq JJ, Zafrani L, Brindele I, Bugnet E, Celli Lebras K, Chabert J, Djaghout L, Fauvaux C, Jegu AL, Kozaliewicz E, Meunier M, Tremorin MT, Davoine C, Madeleine I, Caillat-Zucman S, Delaugerre C, Morin F, SENE D, BURLACU R, CHOUSTERMAN B, MEGARBANE B, RICHETTE P, RIVELINE JP, FRAZIER A, VICAUT E, BERTON L, HADJAM T, VASQUEZ-IBARRA MA, JOURDAINE C, JACOB A, SMATI J, RENAUD S, MANIVET P, PERNIN C, SUAREZ L, Semerano L, ABAD S, Benainous R, Bloch Queyrat C, Bonnet N, Brahmi S, Cailhol J, Cohen Y, Comparon C, Cordel H, Dhote R, Dournon N, Duchemann B, Ebstein N, Giroux-Leprieur B, Goupil de Bouille J, Jacolot A, Nunes H, Oziel J, Rathouin V, Rigal M, Roulot D, Tantet C, Uzunhan Y, COSTEDOAT-CHALUMEAU N, Ait Hamou Z, Benghanem S, BLANCHE P, CANOUI E, CARLIER N, CHAIGNE B, CONTEJEAN A, DUNOGUE B, DUPLAND P, DUREL - MAURISSE A, GAUZIT R, JAUBERT P, Joumaa H, Jozwiak M, KERNEIS S, LACHATRE M, Lafoeste H, LEGENDRE P, LUONG NGUYEN LB, MAREY J, MORBIEU C, MOUTHON L, NGUYEN L, Palmieri LJ, REGENT A, SZWEBEL TA, TERRIER B, GUERIN C, ZERBIT J, CHEREF K, CHITOUR K, CISSE MS, CLARKE A, CLAVERE G, DUSANTER I, GAUDEFROY C, JALLOULI M, KOLTA S, LE BOURLOUT C, MARIN N, MENAGE N, MOORES A, PEIGNEY I, PIERRON C, SALEH-MGHIR S, VALLET M, MICHEL M, MELICA G, LELIEVRE JD, FOIS E, LIM P, MATIGNON M, GUILLAUD C, THIEMELE A, SCHMITZ D, BOUHRIS M, BELAZOUZ S, LANGUILLE L, MEKONTSO-DESSAPS A, SADAOUI T, Mayaux J, Cacoub P, Corvol JC, Louapre C, Sambin S, Mariani LL, Karachi C, Tubach F, Estellat C, Gimeno L, Martin K, Bah A, Keo V, Ouamri S, Messaoudi Y, Yelles N, Faye P, Cavelot S, Larcheveque C, Annonay L, Benhida J, Zahrate-Ghoul A, Hammal S, Belilita R, Lecronier M, Beurton A, Haudebourg L, Deleris R, Le Marec J, Virolle S, Nemlaghi S, Bureau C, Mora P, De Sarcus M, Clovet O, Duceau B, Grisot PH, Pari MH, Arzoine J, Clarac U, Faure M, Delemazure J, Decavele M, Morawiec E, Demoule A, Dres M, Vautier M, Allenbach Y, Benveniste O, Leroux G, Rigolet A, Guillaume-Jugnot P, Domont F, Desbois AC, Comarmond C, Champtiaux N, Toquet S, Ghembaza A, Vieira M, Maalouf G, Boleto G, Ferfar Y, Charbonnier F, AGUILAR C, ALBY-LAURENT F, ALYANAKIAN MA, BAKOUBOULA P, BROISSAND C, BURGER C, CAMPOS-VEGA C, CHAVAROT N, CHOUPEAUX L, FOURNIER B, GRANVILLE S, ISSORAT E, ROUZAUD C, VIMPERE D, Geri G, Derridj N, Sguiouar N, Meddah H, Djadel M, Chambrin-Lauvray H, Duclos-Vallée JC, Saliba F, Sacleux SC, Koumis I, Michot JM, Stoclin A, Colomba E, Pommeret F, Willekens C, Sakkal M, Da Silva R, Dejean V, Mekid Y, Ben-Mabrouk I, Pradon C, Drouard L, Camara-Clayette V, Morel A, Garcia G, Mohebbi A, Berbour F, Dehais M, Pouliquen AL, Klasen A, Soyez-Herkert L, London J, Keroumi Y, Guillot E, Grailles G, El Amine Y, Defrancq F, Fodil H, Bouras C, Dautel D, Gambier N, Dieye T, Razurel A, Bienvenu B, Lancon V, Lecomte L, Beziriganyan K, Asselate B, Allanic L, Kiouris E, Legros MH, Lemagner C, Martel P, Provitolo V, Ackermann F, Le Marchand M, Clan Hew Wai A, Fremont D, Coupez E, Adda M, Duée F, Bernard L, Gros A, Henry E, Courtin C, Pattyn A, Guinot PG, Bardou M, Maurer A, Jambon J, Cransac A, Pernot C, Mourvillier B, Servettaz A, Deslée G, Wynckel A, Benoit P, Marquis E, Roux D, Gernez C, Yelnik C, Poissy J, Nizard M, Denies F, Gros H, Mourad JJ, Sacco E, Renet S. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology 2022; 4:e24-e32. [PMID: 34812424 PMCID: PMC8598187 DOI: 10.1016/s2665-9913(21)00315-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Background Patients with COVID-19 pneumonia can have increased inflammation and elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a high-affinity anti-IL-6 receptor antibody, might improve the outcome of patients with moderate-to-severe COVID-19 pneumonia. Methods We did a multicentric, open-label, Bayesian randomised, adaptive, phase 2/3 clinical trial, nested within the CORIMUNO-19 cohort, to test a superiority hypothesis. Patients 18 years or older hospitalised with COVID-19 in six French centres, requiring at least 3L/min of oxygen but without ventilation assistance and a WHO Clinical Progression Scale [CPS] score of 5 were enrolled. Patients were randomly assigned (1:1) via a web-based system, according to a randomisation list stratified on centre and with blocks randomly selected among 2 and 4, to receive usual care plus 400 mg of sarilumab intravenously on day 1 and on day 3 if clinically indicated (sarilumab group) or usual care alone (usual care group). Primary outcomes were the proportion of patients with WHO-CPS scores greater than 5 on the 10-point scale on day 4 and survival without invasive or non-invasive ventilation at day 14. This completed trial is closed to new participants and is registered with ClinicalTrials.gov, NCT04324073. Findings 165 patients were recruited from March 27 to April 6, 2020, and 148 patients were randomised (68 patients to the sarilumab group and 80 to the usual care group) and followed up for 90 days. Median age was 61·7 years [IQR 53·0–71·1] in the sarilumab group and 62·8 years [56·0–71·7] in the usual care group. In the sarilumab group 49 (72%) of 68 were men and in the usual care group 59 (78%) of 76 were men. Four patients in the usual care group withdrew consent and were not analysed. 18 (26%) of 68 patients in the sarilumab group had a WHO-CPS score greater than 5 at day 4 versus 20 (26%) of 76 in the usual care group (median posterior absolute risk difference 0·2%; 90% credible interval [CrI] −11·7 to 12·2), with a posterior probability of absolute risk difference greater than 0 of 48·9%. At day 14, 25 (37%) patients in the sarilumab and 26 (34%) patients in the usual care group needed ventilation or died, (median posterior hazard ratio [HR] 1·10; 90% CrI 0·69–1·74) with a posterior probability HR greater than 1 of 37·4%. Serious adverse events occurred in 27 (40%) patients in the sarilumab group and 28 (37%) patients in the usual care group (p=0·73). Interpretation Sarilumab treatment did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia. Further studies are warranted to evaluate the effect of sarilumab on long-term survival. Funding Assistance publique—Hôpitaux de Paris
Collapse
|
7
|
Landon-Cardinal O, Bachasson D, Guillaume-Jugnot P, Vautier M, Champtiaux N, Hervier B, Rigolet A, Aggarwal R, Benveniste O, Hogrel JY, Allenbach Y. Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. Semin Arthritis Rheum 2020; 50:1140-1149. [DOI: 10.1016/j.semarthrit.2020.06.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Revised: 05/22/2020] [Accepted: 06/17/2020] [Indexed: 02/01/2023]
|
8
|
Wesner N, Uruha A, Suzuki S, Mariampillai K, Granger B, Champtiaux N, Rigolet A, Schoindre Y, Lejeune S, Guillaume-Jugnot P, Vautier M, Hervier B, Simon A, Granier F, Gallay L, Nishino I, Benveniste O, Allenbach Y. Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. Autoimmun Rev 2020; 19:102465. [PMID: 31918028 DOI: 10.1016/j.autrev.2020.102465] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 10/05/2019] [Indexed: 11/15/2022]
Affiliation(s)
- Nadège Wesner
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Akinori Uruha
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France; Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1, Musashidai, Fuchu, 183-0042 Tokyo, Japan
| | - Shigeaki Suzuki
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan
| | - Kubéraka Mariampillai
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Benjamin Granger
- Department of Public Health, Pitié Salpétrière Hospital, 84 Boulevard de l'Hôpital, 75013 Paris, France
| | - Nicolas Champtiaux
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Aude Rigolet
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Yoland Schoindre
- Internal Medicine Department, Foch Hospital, 40 Rue Worth, 92150 Suresnes, France
| | - Sylvain Lejeune
- Internal Medicine Department, Avicennes Hospital, 125, rue de Stalingrad, 93000 Bobigny, France
| | - Perrine Guillaume-Jugnot
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Matthieu Vautier
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Baptiste Hervier
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Anne Simon
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Françoise Granier
- Internal Medicine Department, Centre Hospitalier François Quesnay, 62 rue Saint Vincent, 78201 Mantes la Jolie, France
| | - Laure Gallay
- Internal Medicine Department, Hospices Civils de Lyon, Neuro-Myo-Gène Institut, INSERM U1217, 68008 Lyon, France
| | - Ichizo Nishino
- Department of Neuromuscular Research, National Institute of Neuroscience and Department of Genome Medicine Development, Medical Genome Center National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, 187-8551 Tokyo, Japan
| | - Olivier Benveniste
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Yves Allenbach
- Department of Internal Medicine and Clinical Immunology, Sorbonne Université, University Pierre et Marie et Curie, APHP, Hôpital Pitié-Salpêtrière, Paris, France.
| |
Collapse
|
9
|
Guillaume-Jugnot P, Guégan S, Léonard-Louis S, Barete S, Benveniste O, Allenbach Y. Infliximab as effective treatment for aseptic neutrophilic myositis. Neurology 2019; 93:1009-1011. [PMID: 31662493 DOI: 10.1212/wnl.0000000000008584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2019] [Accepted: 09/03/2019] [Indexed: 11/15/2022] Open
Affiliation(s)
- Perrine Guillaume-Jugnot
- From the Sorbonne Université (P.G.-J., O.B., Y.A.), INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital; Université Paris Descartes (S.G.), Service de Dermatologie, Hôpital Cochin-Centre Tarnier, APHP; Department of Neurology and Myology (S.L.-L.), Pitié-Salpêtrière Hospital; and Department of Dermatology (S.B.), Pitié-Salpêtrière Hospital, Paris, France.
| | - Sarah Guégan
- From the Sorbonne Université (P.G.-J., O.B., Y.A.), INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital; Université Paris Descartes (S.G.), Service de Dermatologie, Hôpital Cochin-Centre Tarnier, APHP; Department of Neurology and Myology (S.L.-L.), Pitié-Salpêtrière Hospital; and Department of Dermatology (S.B.), Pitié-Salpêtrière Hospital, Paris, France
| | - Sarah Léonard-Louis
- From the Sorbonne Université (P.G.-J., O.B., Y.A.), INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital; Université Paris Descartes (S.G.), Service de Dermatologie, Hôpital Cochin-Centre Tarnier, APHP; Department of Neurology and Myology (S.L.-L.), Pitié-Salpêtrière Hospital; and Department of Dermatology (S.B.), Pitié-Salpêtrière Hospital, Paris, France
| | - Stéphane Barete
- From the Sorbonne Université (P.G.-J., O.B., Y.A.), INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital; Université Paris Descartes (S.G.), Service de Dermatologie, Hôpital Cochin-Centre Tarnier, APHP; Department of Neurology and Myology (S.L.-L.), Pitié-Salpêtrière Hospital; and Department of Dermatology (S.B.), Pitié-Salpêtrière Hospital, Paris, France
| | - Olivier Benveniste
- From the Sorbonne Université (P.G.-J., O.B., Y.A.), INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital; Université Paris Descartes (S.G.), Service de Dermatologie, Hôpital Cochin-Centre Tarnier, APHP; Department of Neurology and Myology (S.L.-L.), Pitié-Salpêtrière Hospital; and Department of Dermatology (S.B.), Pitié-Salpêtrière Hospital, Paris, France
| | - Yves Allenbach
- From the Sorbonne Université (P.G.-J., O.B., Y.A.), INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital; Université Paris Descartes (S.G.), Service de Dermatologie, Hôpital Cochin-Centre Tarnier, APHP; Department of Neurology and Myology (S.L.-L.), Pitié-Salpêtrière Hospital; and Department of Dermatology (S.B.), Pitié-Salpêtrière Hospital, Paris, France
| |
Collapse
|
10
|
Beigneux Y, Arnulf I, Guillaume-Jugnot P, Leu-Semenescu S, Maillart E, Lubetzki C, Benveniste O, Papeix C. Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2019; 38:101869. [PMID: 31785490 DOI: 10.1016/j.msard.2019.101869] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Accepted: 11/23/2019] [Indexed: 11/29/2022]
Abstract
The identification of AQP4-IgG, a specific and pathogenic antibody of NMO/SD has led to a broadening of the clinical spectrum of manifestations of NMO/SD including the presence of encephalic symptoms. Lesions are often distributed on peri‑ependymal area and sometimes affected the diencephalon leading to sleep disorders. We report a case of hypersomnia with polysomnographic documentation during the first attack of NMO/SD. Brain MRI revealed bilateral hypothalamic lesions around the third ventricle, whereas optic nerves and spinal cord were intact. The record of the nocturnal video-polysomnography followed by multiple sleep latency tests (MSLT) revealed an abnormal shortened sleep period with a single sleep onset in REM allowing secondary central hypersomnia diagnosis. The recovery of hypersomnia was complete within few months without psychostimulant treatment and the diencephalic lesion disappeared. Thus, diencephalic form of NMO/SD seems to cause narcolepsy or non-narcoleptic central hypersomnia and have a good recovery.
Collapse
Affiliation(s)
- Ysoline Beigneux
- Département de neurologie, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France.
| | - Isabelle Arnulf
- Service des Pathologies du Sommeil, Centre de Référence narcolepsie et hypersomnies rares, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| | - Perrine Guillaume-Jugnot
- Service de Médecine Interne et Immunologie Clinique, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| | - Smaranda Leu-Semenescu
- Service des Pathologies du Sommeil, Centre de Référence narcolepsie et hypersomnies rares, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| | - Elisabeth Maillart
- Département de neurologie, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| | - Catherine Lubetzki
- Département de neurologie, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| | - Olivier Benveniste
- Service de Médecine Interne et Immunologie Clinique, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| | - Caroline Papeix
- Département de neurologie, Hôpital de la pitié salpêtrière, APHP, Sorbonne Université, Paris 75013, France
| |
Collapse
|
11
|
Landon-Cardinal O, Bachasson D, Guillaume-Jugnot P, Vautier M, Champtiaux N, Hervier B, Rigolet A, Benveniste O, Hogrel J, Allenbach Y. P.195Physical activity monitoring using wrist-worn accelerometer in the assessment of patients with myositis. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.250] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Ledoult E, Groh M, Kahn JE, Trauet J, Bouaziz JD, Caristan A, Cottin V, Dubucquoi S, Etienne N, Golden C, Guillaume-Jugnot P, Hachulla É, Launay D, Machelart I, De Masson A, Molinet T, Morati-Hafsaoui C, Puget M, Roumier M, Terriou L, Meresse B, Dendooven A, Copin MC, Dubois R, Labalette M, Lefèvre G. Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol Pract 2019; 8:1110-1114.e2. [PMID: 31525539 DOI: 10.1016/j.jaip.2019.08.049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 08/28/2019] [Accepted: 08/29/2019] [Indexed: 11/28/2022]
Affiliation(s)
- Emmanuel Ledoult
- Institut d'Immunologie, CHU de Lille, Lille, France; Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France; Département de Médecine Interne, CHU de Lille, Lille, France
| | - Matthieu Groh
- Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France; Département de Médecine Interne, Hôpital Foch, Suresnes, France
| | - Jean-Emmanuel Kahn
- Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France; Département de Médecine Interne, Hôpital Foch, Suresnes, France
| | - Jacques Trauet
- Institut d'Immunologie, CHU de Lille, Lille, France; Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France
| | | | - Aurélie Caristan
- Département de Médecine Interne, CHD Vendée, La Roche sur Yon, France
| | - Vincent Cottin
- Département de Pneumologie, CHU de Lyon HCL, Lyon, France
| | - Sylvain Dubucquoi
- Institut d'Immunologie, CHU de Lille, Lille, France; Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France
| | - Nicolas Etienne
- Département de Médecine Interne, CHU de Lille, Lille, France; Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France
| | - Cécile Golden
- Département de Médecine Interne, CH de Vesoul, Vesoul, France
| | | | - Éric Hachulla
- Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France; Département de Médecine Interne, CHU de Lille, Lille, France; Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France
| | - David Launay
- Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France; Département de Médecine Interne, CHU de Lille, Lille, France; Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France
| | - Irène Machelart
- Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France; Département de Médecine Interne, CHU de Bordeaux, Bordeaux, France
| | - Adèle De Masson
- Département de Dermatologie, Hôpital Saint-Louis, Paris, France
| | - Thomas Molinet
- Département de Médecine Interne, CHU de Nancy, Nancy, France
| | - Chafika Morati-Hafsaoui
- Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France; Département de Médecine Interne, CH d'Annecy-Genevois, Epagny Metz-Tessy, France
| | - Marie Puget
- Département de Médecine Interne, CH de Valence, Valence, France
| | | | - Louis Terriou
- Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France; Département de Médecine Interne, CHU de Lille, Lille, France; Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France
| | - Bertrand Meresse
- Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France
| | - Arnaud Dendooven
- Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France; Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France
| | | | | | - Myriam Labalette
- Institut d'Immunologie, CHU de Lille, Lille, France; Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France
| | - Guillaume Lefèvre
- Institut d'Immunologie, CHU de Lille, Lille, France; Univ. Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France; Département de Médecine Interne, CHU de Lille, Lille, France; Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), Lille, France.
| | | |
Collapse
|
13
|
Landon-Cardinal O, Bachasson D, Guillaume-Jugnot P, Vautier M, Champtiaux N, Hervier B, Rigolet A, Benveniste O, Hogrel J, Allenbach Y. Évaluation de l’activité physique par accélérométrie de poignet dans le suivi des patients avec myopathies auto-immunes. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Vautier M, Schmidt J, Berezne A, Cordel N, Duffau P, Graveleau J, Jachiet M, Chosidow O, Rigolet A, Guillaume-Jugnot P, Benveniste O, Allenbach Y. Dermatomyosite et anticorps anti-SAE : des patients peu déficitaires avec un risque accru de troubles de la déglutition et de pneumopathie organisée. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Wesner N, Uruha A, Costedoat-Chalumeau N, Rigolet A, Schoindre Y, Le Jeune S, Gilardin L, Guillaume-Jugnot P, Champtiaux N, Benveniste O, Allenbach Y, Vautier M, Hervier B, Simon A, Granier F. Myosites associées aux anticorps anti-RNP : un phénotype homogène avec une atteinte nécrosante de bon pronostic et des manifestations systémiques persistantes. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Koumakou C, Landon-Cardinal O, Granger B, Vautier M, Reyngoudt H, Rigolet A, Champtiaux N, Guillaume-Jugnot P, Hervier B, Carlier P, Benveniste O, Allenbach Y. IRM musculaire corps entier au cours des myopathies nécrosantes auto-immunes : involution graisseuse sévère axiale et pelvi-fémorale. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Pugnet G, Castilla-Llorente C, Puyade M, Terriou L, Badoglio M, Deligny C, Guillaume-Jugnot P, Labeyrie C, Benzidia I, Faivre H, Lansiaux P, Marjanovic Z, Bourhis JH, Faucher C, Furst S, Huynh A, Martin T, Vermersch P, Yakoub-Agha I, Farge D. [Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2017; 104:S169-S180. [PMID: 29173974 DOI: 10.1016/j.bulcan.2017.06.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Accepted: 06/27/2017] [Indexed: 12/15/2022]
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2017 in Lille, France and updated recommendations for indications and follow-up in autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases, previously published under the auspices of SFGM-TC.
Collapse
Affiliation(s)
- Grégory Pugnet
- CHU de Toulouse, hôpital Purpan, service de médecine interne, 1, place Baylac, 31059 Toulouse, France
| | | | - Mathieu Puyade
- Cité hospitalière de la Milétrie, hôpital Jean-Bernard, service d'hématologie, 2, rue de la Milétrie, 86021 Poitiers cedex, France
| | - Louis Terriou
- CHRU, hôpital Claude-Huriez, service des maladies du sang, rue Michel-Polonovski, 59037 Lille cedex, France
| | - Manuela Badoglio
- Hôpital Saint-Antoine, EBMT data office, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France
| | - Christophe Deligny
- CHU de Fort-de-France, service de médecine interne-rhumatologie, 97261 Fort-de-France, Martinique
| | - Perrine Guillaume-Jugnot
- Hôpital Pitié-Salpêtrière, service de médecine interne, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - Céline Labeyrie
- CHU Bicêtre, centre de référence national NNERf, service de neurologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - Ilham Benzidia
- Hôpital Saint-Louis, UF04, unité de médecine interne, maladies auto-immunes et pathologie vasculaire, centre de référence des maladies auto-immunes systémiques rares d'Ile-de-France, Filière 'FAI2R', 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - Hélène Faivre
- Hôpital Saint-Louis, UF04, unité de médecine interne, maladies auto-immunes et pathologie vasculaire, centre de référence des maladies auto-immunes systémiques rares d'Ile-de-France, Filière 'FAI2R', 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - Pauline Lansiaux
- Hôpital Saint-Louis, UF04, unité de médecine interne, maladies auto-immunes et pathologie vasculaire, centre de référence des maladies auto-immunes systémiques rares d'Ile-de-France, Filière 'FAI2R', 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - Zora Marjanovic
- AP-HP, hôpital Saint-Antoine, hématologie clinique et thérapie cellulaire, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France
| | - Jean-Henri Bourhis
- Institut Gustave-Roussy, service d'hématologie, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Catherine Faucher
- Institut Paoli-Calmettes, unité de transplantation et de thérapie cellulaire (U2t), service oncologie et hématologie, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Sabine Furst
- Institut Paoli-Calmettes, unité de transplantation et de thérapie cellulaire (U2t), service oncologie et hématologie, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France
| | - Anne Huynh
- Oncopole, institut universitaire du cancer Toulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
| | - Thierry Martin
- Hôpital civil, service de médecine interne et immunologie clinique, 1, place de l'hôpital, BP 426, 67091 Strasbourg cedex, France
| | - Patrick Vermersch
- CHRU de Lille, service de neurologie générale et pathologie neuro-inflammatoire, 2, avenue Oscar-Lambret, 59037 Lille cedex, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, université de Lille 2, LIRIC Inserm U995, 59000 Lille, France.
| | - Dominique Farge
- Hôpital Saint-Louis, UF04, unité de médecine interne, maladies auto-immunes et pathologie vasculaire, centre de référence des maladies auto-immunes systémiques rares d'Ile-de-France, Filière 'FAI2R', 1, avenue Claude-Vellefaux, 75475 Paris, France.
| |
Collapse
|
18
|
Guillaume-Jugnot P, Daumas A, Magalon J, Sautereau N, Veran J, Magalon G, Sabatier F, Granel B. State of the art. Autologous fat graft and adipose tissue-derived stromal vascular fraction injection for hand therapy in systemic sclerosis patients. Curr Res Transl Med 2016; 64:35-42. [PMID: 27140597 DOI: 10.1016/j.retram.2016.01.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Accepted: 01/04/2016] [Indexed: 01/27/2023]
Abstract
Systemic sclerosis is an autoimmune disease characterized by sclerosis (hardening) of the skin and deep viscera associated with microvascular functional and structural alteration, which leads to chronic ischemia. In the hands of patients, ischemic and fibrotic damages lead to both pain and functional impairment. Hand disability creates a large burden in professional and daily activities, with social and psychological consequences. Currently, the proposed therapeutic options for hands rely mainly on hygienic measures, vasodilatator drugs and physiotherapy, but have many constraints and limited effects. Developing an innovative therapeutic approach is crucial to reduce symptoms and improve the quality of life. The discovery of adult stem cells from adipose tissue has increased the interest to use adipose tissue in plastic and regenerative surgery. Prepared as freshly isolated cells for immediate autologous transplantation, adipose tissue-derived stem cell therapy has emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. We aim to update literature in the interest of autologous fat graft or adipose derived from stromal vascular fraction cell-based therapy for the hands of patients who suffer from systemic sclerosis.
Collapse
Affiliation(s)
- P Guillaume-Jugnot
- Service de médecine interne, hôpital Nord, Assistance publique-Hôpitaux de Marseille (AP-HM), 13915 Marseille cedex 05, France
| | - A Daumas
- Service de médecine interne, gériatrie et thérapeutique, hôpital de la Timone, AP-HM, 13385 Marseille cedex 05, France
| | - J Magalon
- Laboratoire de culture et thérapie cellulaire, Inserm CBT-1409, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France
| | - N Sautereau
- Service de médecine interne, hôpital Nord, Assistance publique-Hôpitaux de Marseille (AP-HM), 13915 Marseille cedex 05, France
| | - J Veran
- Laboratoire de culture et thérapie cellulaire, Inserm CBT-1409, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France
| | - G Magalon
- Service de chirurgie plastique et réparatrice, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France
| | - F Sabatier
- Laboratoire de culture et thérapie cellulaire, Inserm CBT-1409, hôpital de la Conception, AP-HM, 13385 Marseille cedex 05, France; Inserm UMR 1076 Vascular Research Centre of Marseille, Aix-Marseille université, 13385 Marseille cedex 05, France
| | - B Granel
- Service de médecine interne, hôpital Nord, Assistance publique-Hôpitaux de Marseille (AP-HM), 13915 Marseille cedex 05, France; Inserm UMR 1076 Vascular Research Centre of Marseille, Aix-Marseille université, 13385 Marseille cedex 05, France.
| |
Collapse
|
19
|
Guillaume-Jugnot P, Daumas A, Magalon J, Jouve E, Nguyen PS, Truillet R, Mallet S, Casanova D, Giraudo L, Veran J, Dignat-George F, Sabatier F, Magalon G, Granel B. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology (Oxford) 2015; 55:301-6. [PMID: 26350489 DOI: 10.1093/rheumatology/kev323] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived stromal vascular fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months. METHODS Twelve females, mean age 54.5 years (s.d. 10.3), were assessed 1 year after ADSVF injection. Patients were eligible if they had a Cochin Hand Function Scale score >20/90. ADSVF was obtained from lipoaspirate using an automated processing system and subsequently injected into the s.c. tissue of each finger in contact with neurovascular pedicles in a one-time procedure. Endpoints were changes in hand disability and skin fibrosis, vascular manifestations, pain and quality of life at the 12 month follow-up. During the visit, patients estimated the benefit of the procedure with a specific self-completed questionnaire. RESULTS A significant decrease from baseline of 51.3% (P < 0.001) for Cochin Hand Function Scale score, 63.2% (P < 0.001) for RP severity and 46.8% (P = 0.001) for quality of life (Scleroderma Health Assessment Questionnaire) was observed. A significant improvement of finger oedema, skin sclerosis, motion and strength of the hands and of the vascular suppression score was also noted. The reduction in hand pain approached statistical significance (P = 0.052). The questionnaire revealed a benefit in daily activities, housework and social activities. CONCLUSION ADSVF injection is a promising therapy and appears to have benefits that extend for at least 1 year.
Collapse
Affiliation(s)
| | | | - Jérémy Magalon
- Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseilles, Aix-Marseilles University
| | - Elisabeth Jouve
- Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques, Assistance Publique Hôpitaux de Marseilles
| | | | - Romain Truillet
- Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques, Assistance Publique Hôpitaux de Marseilles
| | | | | | - Laurent Giraudo
- Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseilles, Aix-Marseilles University
| | - Julie Veran
- Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseilles, Aix-Marseilles University
| | - Françoise Dignat-George
- Hematology and Vascular Biology Laboratory, Assistance Publique Hôpitaux de Marseilles and Vascular Research Center Marseille, INSERM UMRS-1076, Aix-Marseilles University, Marseilles, France
| | - Florence Sabatier
- Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseilles, Aix-Marseilles University, Hematology and Vascular Biology Laboratory, Assistance Publique Hôpitaux de Marseilles and Vascular Research Center Marseille, INSERM UMRS-1076, Aix-Marseilles University, Marseilles, France
| | - Guy Magalon
- Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques, Assistance Publique Hôpitaux de Marseilles, Plastic Surgery Department
| | - Brigitte Granel
- Internal Medicine Department and Vascular Research Center Marseille, INSERM UMRS-1076, Aix-Marseilles University, Marseilles, France
| |
Collapse
|
20
|
Hij A, Dahmani R, Perroteau F, Cailleteau R, Kurihara F, Guillaume-Jugnot P, Algayres J, Farge D. Fièvre au cours d’une thrombose veineuse sous traitement anticoagulant révélant une maladie de Behçet. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Hij A, Guillaume-Jugnot P, Kurihara F, Cailleteau R, Perroteau F, Dahmani R, Dumitroaia A, Farge D, Algayres J. Nocardiose cérébrale après autogreffe de cellules souches hématopoïétiques chez une patiente sclérodermique. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Guillaume-Jugnot P, Badoglio M, Hij A, Wu C, Pugnet G, Chatelus E, Martin T, Terriou L, Lioure B, Yakoub-Agha I, Marjanovic Z, Farge D. Survie globale des patients traités par greffe de cellules souches hématopoïétiques (CSH) autologue pour maladie auto-immune (MAI) sévère : analyse de l’activité en France depuis 1997. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Guillaume-Jugnot P, Daumas A, Jouve E, Truillet R, Mallet S, Serratrice J, Swiader L, Veran J, Dignat-George F, Sabatier F, Magalon G, Granel B. Évaluation à 1 an de l’injection sous-cutanée de la fraction vasculaire stromale autologue d’origine adipeuse au niveau des doigts chez les patients atteints de sclérodermie systémique. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Guillaume-Jugnot P, Horreau C, Kheloufi F, Jean Pastor M, Brajon D, Berbis P. DRESS syndrome à la daltéparine sodique : première observation. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Seguier J, Guillaume-Jugnot P, Ebbo M, Daniel L, Jourde-Chiche N, Burtey S, Bernit E, Thomas P, Harlé JR, Schleinitz N. [Thymic disease associated with nephrotic syndrome: a new case with membranous nephropathy and literature review]. Rev Med Interne 2014; 36:487-90. [PMID: 25172778 DOI: 10.1016/j.revmed.2014.07.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 05/02/2014] [Accepted: 07/22/2014] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Malignant thymoma or thymic hyperplasia is associated with various autoimmune diseases. Renal disease has rarely been reported in this condition. We report a new case with improvement of renal disease after thymectomy. CASE REPORT A 77-year-old-women with nephritic syndrome was found to have associated thymic mass. Renal pathology showed membranous nephropathy. The thymic mass pathology showed a B2 type thymoma. After thymectomy the nephrotic syndrome improved. CONCLUSION Glomerulopathy can be secondary to an acquired thymic disease. Membranous nephropathy but also other glomerular diseases can be observed often presenting with nephritic syndrome. Despite the rarity of this association this clinical observation underlines that a thymoma should be searched in the presence of a glomerulopathy. The glomerulopathy can be improved by the treatment of the thymoma.
Collapse
Affiliation(s)
- J Seguier
- Service de médecine interne, Aix Marseille université, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France.
| | - P Guillaume-Jugnot
- Service de médecine interne, Aix Marseille université, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France
| | - M Ebbo
- Service de médecine interne, Aix Marseille université, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France
| | - L Daniel
- Service d'anatomopathologie, Aix Marseille université, AP-HM, 13385 Marseille cedex 5, France
| | - N Jourde-Chiche
- Service de néphrologie et transplantation rénale, Aix Marseille université, AP-HM, 13385 Marseille cedex 5, France
| | - S Burtey
- Service de néphrologie et transplantation rénale, Aix Marseille université, AP-HM, 13385 Marseille cedex 5, France
| | - E Bernit
- Service de médecine interne, Aix Marseille université, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France
| | - P Thomas
- Service de chirurgie thoracique, Aix Marseille université, AP-HM, 13385 Marseille cedex 5, France
| | - J-R Harlé
- Service de médecine interne, Aix Marseille université, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France
| | - N Schleinitz
- Service de médecine interne, Aix Marseille université, AP-HM, 147, boulevard Baille, 13385 Marseille cedex 5, France
| |
Collapse
|
26
|
Guillaume-Jugnot P, Bioul C, Horreau C, Kheloufi F, Secq V, Ebbo M, Jean-Pastor M, Brajon D, Harle J, Berbis P. Étonnant cas de DRESS syndrome induit à la daltéparine sodique. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Guillaume-Jugnot P, Khibri H, Ebbo M, Colavolpe C, Guedj E, Bernit E, Christides C, Harle JR, Schleinitz N. 18FDG TEP/TDM itératives et diagnostic du lymphome B intravasculaire. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Khibri H, Guillaume-Jugnot P, Ebbo M, Bernit E, Bono W, Veit V, Alessi MC, Pouymayou K, Morange PE, Schleinitz N, Harlé JR. Circonstances de découverte, complications hémorragiques et pathologies associées au syndrome de Willebrand acquis : expérience d’un centre régional. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Khibri H, Ebbo M, Guillaume-Jugnot P, Grados A, Frances J, Burtey S, Vacher-Coponat H, Bernit E, Daniel L, Harle J, Schleinitz N. Lymphome B de haut grade compliquant une maladie associée aux IgG4 : Intérêt du dosage des chaînes légères libres ? Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|